Introduction {#Sec1}
============

Intractable chronic neck pain after a whiplash trauma is a major burden for patients, healthcare providers and insurance companies. It is estimated that 14--42% of patients develop chronic symptoms after an acute whiplash trauma \[[@CR2]\].

These patients often have reduced mobility of the neck with tender muscles and increased muscle activity \[[@CR25]\]. Pathophysiology is still unknown, but myofascial triggerpoints can develop in cervical muscles from excessive neck and shoulder muscle contraction due to an overt injury such as acceleration of the neck in a motor vehicle accident \[[@CR5]\]. Botulinum toxin is used to treat a variety of neurological disorders associated with pathologically increased muscle tone.

Two previous studies have reported that botulinum toxin might be successful in patients with chronic neck pain following whiplash injuries \[[@CR6], [@CR12]\]. These studies were uncontrolled and the follow-up period was relatively short. In a randomized placebo- controlled trial involving 26 patients with chronic neck complaints after whiplash injury a significant improvement on total pain was suggested \[[@CR7], [@CR8]\].This study however has some methodological problems, such as a relatively short follow-up period of 4 weeks and a small sample size \[[@CR7], [@CR8]\]. Based upon the present evidence botulinum toxin cannot be recommended as standard treatment for chronic neck pain after whiplash injury.

We therefore conducted a double blind placebo-controlled randomized trial to confirm if botulinum toxin in treatment of neck pain is indeed effective in chronic whiplash syndrome.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Patients were eligible if they had a whiplash type neck distortion defined as a soft tissue injury of the neck following a vehicle collision, with symptoms lasting longer than 6 months. They also met criteria of the Quebec Task Force grade 1 or 2 whiplash-associated disorders (WAD). WAD grade 1 means only neck pain and stiffness and grade 2 requires also musculoskeletal signs, e.g. a decreased range of motion \[[@CR24]\]. Exclusion criteria were: age \< 18; pregnancy; neuromuscular disorders; previous use of other investigational new drugs in the past 30 days prior to the screening visit; previous use of botulinum toxin; traumatic abnormalities on radiological examinations. The institutional ethics committee approved the study protocol, and patients gave informed consent before inclusion.

Study design {#Sec4}
------------

The trial had a double-blind, placebo-controlled parallel design. After patient's consent was obtained, we recorded demographics (age, gender). During a baseline-period of 4 weeks, patients used a diary to record the presence of neck pain, number of neck pain hours per day, number of days on which medication was taken, and number of tablets taken per day. At the end of this baseline-period (week 0) patients recorded their mean neck pain intensity scored on 100 mm Visual Analogue Scale of the previous 4 weeks (week --4 to 0, VAS-pre-treatment). At week 0, patients were randomly assigned to receive 100 units botulinum toxin (Botox®) or placebo (saline) in 2 cc syringes. At 12 weeks follow-up they recorded again their mean neck pain intensity of the previous 12 weeks (week 0 to 12, VAS-post-treatment). The local trial pharmacist prepared the drug, coded the syringes, and kept treatment codes. The pharmacist had no further participation in the trial. An experienced clinical neurophysiologist (D.T.) performed all injections. Injection sites were selected individually (i.e. 'follow the pain' approach) in muscles with clinically increased muscle tone or muscle tenderness, and included m. occipitofrontalis, m.temporalis, m. masseter, m. sternocleidomastoideus, m. splenius capitis, m. trapezius and m. semispinalis.

Outcomes {#Sec5}
--------

After patients were injected at week 0 in one single treatment-session, clinical characteristics were recorded using diaries during the 12 weeks post-treatment. The primary outcome measure was the intensity of the neck pain of the total study period, week 0--12, scored on the VAS at week 12 (one single measurement) compared with baseline (VAS week --4 to 0). Patients were asked to rate (in a single value) severity of neck pain which at times may be mild and perhaps at others severe, by "integrating severity over time".

Secondary outcome measures were average number of neck pain days, average number of neck pain hours per day, average number of days on which symptomatic treatment was taken, mean number of symptomatic tablets per day at 12 weeks compared with baseline. Additionally, a blinded investigator asked patients whether there was any improvement in their condition after 4, 8 and 12 weeks in the two treatment groups (five-point scale: great worsening, any worsening, no improvement, any improvement and great improvement). Range of cervical motion was measured with a cervical range of motion (CROM) device to measure the six conventional movements of the spine at week 12 compared with baseline. For measurements of CROM, the patients were seated in a chair with their shoulders supported on a backrest. Patients were instructed to assume a comfortable position and then to perform each required movement and return to the start position. The movements were assessed in this order: right rotation, left rotation, right flexion, left flexion, extension, flexion and then summated to determine the mean total range of motion.

We also divided all patients in responders and non-responders at week 12. We considered at least 45% reduction in the VAS compared with baseline to be clinically relevant (e.g. responder). All adverse events during the 3 months follow-up were recorded by the investigators.

Sample size determination {#Sec6}
-------------------------

At baseline we expected mean neck pain intensity on the VAS of 40/100 mm. The estimated placebo effect was a 8 mm reduction to a VAS intensity of 32/100 at 12 weeks. We hypothesized a 18 mm reduction in the treatment group to a VAS intensity of 22/100, although there are no earlier data on treatment effect of BTX in these patients. To detect this clinically relevant effect (8 versus 18 mm improvement) at a 5% level of statistical significance (two-tailed), with a power of 80%, a total of 40 patients was needed.

Statistical analysis {#Sec7}
--------------------

We calculated mean differences between baseline VAS data and VAS data after 12 weeks, using the t-test; statistical uncertainty was expressed in 95% confidence intervals. The responders at week 12 in each treatment group and the differences in improvement scores were compared by use of the Chi-square test. All these analysis were done with SPSS (version 10.0).

Results {#Sec8}
=======

Between November 1999 and March 2003 40 patients were included at Leyenburg hospital The Hague. Of the 59 patients assessed for eligibility, 19 patients were excluded. Four patients did not meet the inclusion criteria, eight patients refused to participate and seven patients withdrew in the baseline period. No patient was lost to follow-up.

In 1 patient the neck pain diary was incomplete during the whole study period (missing data on neck pain duration, days on which medication was taken and mean number of tablets per day). In 7 patients the neck pain diary for the post-treatment period was partly incomplete (missing data on neck pain duration, days on which medication was taken and mean number of tablets per day). There were no differences in baseline characteristics between the two treatment groups. Neck pain intensity, VAS at baseline was 64.5 mm (SD = 14.8) in the botulinum group and 62.1 (SD = 20.3) in the placebo group (Table [1](#Tab1){ref-type="table"}). Table 1Baseline characteristicsCharacteristicBotulinum toxin (n = 20)Placebo (n = 20)Mean age, years (range)39 (20--58)34 (20--49)Female sex (%)14 (70%)13 (65%)Ongoing claims15 (75%)18 (90%)Mean duration of pain, months (SD)40 (71)37 (20)Neck pain severity, mean VAS (SD)64.5 (14.8)62.1 (20.3)Mean number of neck pain days, % (SD)97% (11) \*^1^96% (12)Mean neck pain duration per day, hours (SD)12.7 (4.0) \*^3^11.7 (4.5)Mean number of medication days, % (SD)50% (41) \*^1^36% (40)Mean number of analgesics per day, tablets (SD)1.4 (1.9)1.3 (2.1)Mean total cervical range of motion, degrees (SD)266 (73) \*^1^266 (60) \*^1^\*^1 ^= one missing data; \*^3 ^= three missing data

At 12 weeks the VAS scores were 52.0 mm (SD = 29.2) in the botulinum group and 56.7 mm (SD = 29.6) in the placebo group. Mean differences between VAS pre- and post-treatment was 12.5 in the botulinum group and 5.5 in the placebo group. The therapeutic gain ( = difference in improvement between the two treatment groups measured in mm) was --7.0 (p = 0.31; 95% CI (--20.7 to + 6.7)). Six patients in the botulinum group were responders as defined, versus four in the placebo group (NS, p = 0.5).

Patients' assessment of improvement/worsening showed no significant difference between the two groups at week 4 (p = 0.9), week 8 (p = 0.4) and 12 (p = 0.4) (Table [2](#Tab2){ref-type="table"}). Table 2Improvement scaleImprovementAt 4 weeksAt 8 weeksAt 12 weeksBotulinum toxin (n = 20)Placebo (n = 20)Botulinum toxin (n = 20)Placebo (n = 20)Botulinum toxin (n = 20)Placebo (n = 20)Great worsening400212Any worsening241423No improvement688768Any improvement555454Great improvement236363Total19\*^1^2020202020\*^1 ^= one missing data

There were no significant differences between the two treatment groups in mean number of neck pain days, mean number of neck pain hours per day, mean number of days on which medication was taken, and mean number of tablets taken per day pre- and post-treatment (Table [3](#Tab3){ref-type="table"}). Table 3Secondary outcome measuresOutcomeBotulinum toxin (n = 20)Placebo (n = 20)Therapeutic gain (95% CI)Neck pain days (% ± SD)  Baseline (4 weeks)97% (11) \*^1^96% (12)  Post-treatment (12 weeks)89% (23) \*^2^89% (25) \*^2^  Mean difference8% (18)7% (22)−1% (−15% to + 13%)Neck pain duration (hours/day ± SD)  Baseline (4 weeks)12.7 (4.0) \*^3^11.7 (4.5)  Post-treatment (12 weeks)12.2 (4.6) \*^7^11.0 (5.1) \*^2^  Mean difference0.86 (2.2)0.72 (4.7)−0.14 (−3.0 to + 2.7)Days on which analgesics were taken (% ± SD)  Baseline (4 weeks)49% (42%)35% (40%)  Post-treatment (12 weeks)42% (38%) \*^3^24% (32%) \*^2^  Mean difference6.4% (16%)5.7% (24%)0.7% (−15% to + 13%)Number of analgesics taken per day (tablets/day ± SD)  Baseline (4 weeks)1.4 (1.9) \*^1^1.3 (2.1)  Post-treatment (12 weeks)1.2 (1.8) \*^2^0.95 (1.9) \*^1^  Mean difference0.32 (0.8)0.18 (0.6)−0.14 (−0.6 to + 0.4)Total cervical range of motion (degrees ± SD)  Baseline266 (73) \*^1^266 (60) \*^1^  Post-treatment (week 12)293 (59) \*^2^277 (62) \*^3^  Mean difference22 (43)11 (36)−11 (−40 to + 17)\*^1^ = one missing data; \*^2^ = two missing data; \*^3^ = three missing data \*^7^ = seven missing data

At baseline all patients showed a reduced cervical range of motion (CROM) in all directions \[[@CR9]\]. There was a slight improvement in total CROM in favour of the botulinum group. However, CROM was not significantly different between BTX group and placebo, nor between responders and non-responders.

Twenty-seven patients reported minor side-effects, 15 in the botulinum toxin group and 12 in the placebo group. The main complaint was "short-lasting pain at the injection sites".

Discussion {#Sec9}
==========

Our study could not demonstrate botulinum toxin to be more effective than placebo in treatment of neck pain in patients with chronic whiplash syndrome.

Previous open label studies with botulinum toxin in patients with chronic whiplash syndrome suggested some beneficial effect on neck pain \[[@CR12]\]. Our study is the second published randomized-controlled trial to determine efficacy of botulinum toxin in patients with chronic whiplash syndrome. The other randomized placebo-controlled trial in 26 patients with chronic whiplash syndrome reported a beneficial effect of botulinum toxin \[[@CR7], [@CR8]\].

This study, however, has some methodological shortcomings. Primary outcome was improvement of headache intensity scored on the VAS after 4 weeks compared with baseline. The post treatment difference between the two treatment groups was reported to be significant. However, baseline-characteristics were significantly different, with a significant higher headache intensity in the botulinum group at baseline. (VAS 6.5 (range 2--9) versus 3.0 (0--8) in the placebo group (p \< 0.01)). The reported improvement may mainly have been caused by the unequal distribution of the patients at baseline. In their second publication ( on the same trial) the mean total pain score was reported, ranging from 0--30, expressing the total pain experience for neck pain, headache and shoulder pain. After 4 weeks the mean total pain was 10.0 (SE 1.3) in the botulinum group and 14.1(SE 21) in the placebo group, which was also reported to be significant. These data are difficult to interpret without individual scores. Calculation of the standard deviation could suggest that some patients even had a negative mean total pain score. In any case, the distribution was truncated and skew to the right.

There are some points of discussion in our study. We used injections at trigger points on an individual basis, instead of following a standardized protocol. This might seem subjective and arbitrary, but resembles clinical practice and is usually recommended for botulinum toxin (BTX) treatment in pain syndromes \[[@CR10], [@CR16]\]. We used doses of 100 U Botox®, which should be sufficient for a single treatment session. There was only slight, not significant, improvement of cervical range of motion in the botulinum group, suggesting some, if any, effect on muscle tenderness. Also, none of our patients reported muscular weakness as a side effect. Therefore, further increase of the dosage of botulinum toxin might be possible. There is some evidence that multiple treatment sessions are needed for sufficient clinical benefit \[[@CR20]\]. In our study there was not even a trend for a positive treatment effect after this single treatment session of BTX. Still, a positive effect of multiple treatment injections cannot be entirely ruled out \[[@CR16]\].

Pathophysiology of chronic pain in whiplash syndrome is still a matter of debate. There is evidence that myofascial pain is a major factor in chronic pain syndromes like chronic neck pain and chronic tension-type headache \[[@CR14]\]. The hypothesis of BTX being effective in chronic whiplash syndrome could be pain reduction by decreasing muscle tenderness and/or activity. If increased muscle tenderness is a key feature in chronic neck pain after a whiplash injury, a more beneficial effect of BTX would have been expected. However, in other chronic pain syndromes where muscle tenderness is thought to play a role BTX was also proven ineffective \[[@CR17], [@CR23]\]. BTX might only be effective in neck pain in combination with cervical dystonia \[[@CR26]\]. In our study were no patients with cervical dystonia.

Patients with chronic whiplash syndrome also form a very heterogeneous group, with a wide spectrum of symptoms, varying from neck pain to headache, with pain of different degrees. Many different factors seem to play a role in the development of acute and chronic pain after a whiplash injury.

There is ample evidence that central mechanisms might play a more important role in the development of chronic neck pain in whiplash patients \[[@CR4]\], as in other chronic pain syndromes. Damaged peripheral tissue releases inflammatory mediators (like bradykinine and prostaglandins) that changes the sensitivity of high-threshold nociceptors (peripheral sensitization). This, in turn, sets up changes in the responsiveness of neurons in the central nervous system (CNS), ultimately increasing the excitability of neurons within the CNS, representing central sensitization \[[@CR21]\]. Patients with chronic whiplash syndrome display exaggerated pain after sensory stimulation as a consequence of this state of hyperexcitability of the central nociceptive system \[[@CR1], [@CR13]\]. In other words, an alteration in function of the central nervous system, the way it responds to normal inputs, seems present in these patients.

This central hypersensivity is probably independent of the nociceptive input arising from the painful and tender muscles \[[@CR4]\], and possibly a consequence of deficient pain inhibitory systems.

Many somatic, psychological or cultural factors may influence central sensitization. Different studies show that prognosis of chronic whiplash syndrome is also dependent on cultural factors \[[@CR15], [@CR18], [@CR22]\]. It has even been shown that presence or absence of compensation claims is one of the most important predictors of bad outcome in patients after whiplash injury (also present in our group in 75--90% of the patients) \[[@CR11], [@CR19]\]. The etiological contribution of all different psychological factors, like for example coping style \[[@CR3]\], to central sensitization is not yet clarified. It is not to be predicted that BTX will improve all different factors, especially psychological and cultural factors, which may contribute to development of this chronic whiplash syndrome.

Based on present evidence BTX cannot be recommended as treatment for neck pain in chronic whiplash patients. Future studies directed on possible central mechanisms of this complicated chronic pain syndrome are warranted.
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